CureVac (CVAC) has released an update.
CureVac, a biopharmaceutical firm specializing in mRNA technology, is streamlining operations by cutting 150 positions and reports a U.S. FDA Fast Track designation for its avian flu vaccine developed with GSK. Amidst ongoing patent litigation with Pfizer/BioNTech, the company maintains a healthy cash reserve of €300.2 million, ensuring a runway into Q4 2025.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
